On July 17, 2023, BridgeBio Pharma announced positive 30-month data from their phase 3 study of acoramidis in ATTR-CM, clearing the way for regulatory submission of a New Drug Application (NDA) before the end of 2023. An investigational, next-generation, orally administered, highly potent, small molecule stabilizer of transthyretin, 30-month results of the ATTRibute-CM trial suggest use was associated with statistically significant improvement in the study's primary endpoint and an 81% on-treatment survival rate, which correlated to an absolute risk reduction for mortality of 6.43% and a relative risk reduction of 25% compared to placebo therapy.